We are thrilled to announce that AKOLS has secured a commercialization grant following a successful pitch at the recent innovation showcase hosted by the Centre for Innovations and Technology Transfer (CITT) at Mbarara University of Science and Technology (MUST). This grant marks a significant milestone in our journey to bring DERMARLIC Tincture, a herbal topical formulation for eczema relief, to a broader market.
Message from the Principal Investigator, Mr. Kagimu Braize Ben
We’re excited to announce that DERMARLIC Tincture has secured critical funding to advance into commercialization, a milestone made possible by our partners, mentors, and dedicated team. We extend profound gratitude to Mr. Anyole Arthur, whose visionary leadership and early-stage funding propelled this project from ideation to prototyping. His belief in DERMARLIC Tincture’s potential laid the foundation for every subsequent achievement. The collaborative partnerships that guided DERMARLIC Tincture through prototyping and the National Drug Authority (NDA) approval. We are deeply indebted to CITT, under the exemplary stewardship of the Director, Dr. Medard Twinamatsiko, for their seed grant, mentorship, and innovation platforms. Special recognition goes to Dr. Jonans Tusimiire, our project mentor, whose technical expertise and guidance sharpened our strategy at every phase.
Our partnership with MUST Holdings Company marks a transformative phase, opening access to business expertise, markets, and distribution channels to reach underserved communities in Uganda.
The journey continues, and the best is yet to come. Thank you for being part of this story.
What’s Next?
With new funding and strategic alliances, we’re preparing to scale up production, expand market reach, and strengthen our impact on public health. We reaffirm our mission: To bring DERMARLIC Tincture to those who need it most.”
